Royal Bank Of Canada Cyma Bay Therapeutics, Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $288,102 - $558,185	22,811 Added 31.93%	94,260 $2.23 Million
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $709,820 - $1.15 Million	65,361 Added 1073.6%	71,449 $1.07 Million
Q2 2023 Aug 14, 2023	BUY	$7.47 - $10.95 $45,283 - $66,378	6,062 Added 23315.38%	6,088 $66,000
Q1 2023 May 15, 2023	SELL	$5.88 - $9.59 $62,051 - $101,203	-10,553 Reduced 99.75%	26 $0
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $9,653 - $18,797	2,998 Added 39.55%	10,579 $66,000
Q3 2022 Nov 14, 2022	BUY	$2.77 - $4.25 $17,536 - $26,906	6,331 Added 506.48%	7,581 $27,000
Q2 2022 Aug 15, 2022	SELL	$1.72 - $3.39 $6,843 - $13,488	-3,979 Reduced 76.09%	1,250 $4,000
Q1 2022 May 16, 2022	SELL	$2.77 - $3.64 $23,495 - $30,874	-8,482 Reduced 61.86%	5,229 $16,000
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $16,489 - $23,483	5,105 Added 59.32%	13,711 $46,000
Q3 2021 Nov 15, 2021	BUY	$3.47 - $4.42 $8,522 - $10,855	2,456 Added 39.93%	8,606 $31,000
Q2 2021 Aug 16, 2021	BUY	$3.94 - $4.92 $24,231 - $30,258	6,150 New	6,150 $27,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.